Umbralisib, a Novel PI3Kδ and Casein Kinase-1ε Inhibitor, in Relapsed or Refractory Chronic Lymphocytic Leukaemia and Lymphoma: an Open-label, Phase 1, Dose-escalation, First-in-human Study

Drug Category: Array
Conference Category: Array
Lead Author: Burris H, et al.
Published Date: 20/02/2018
Download Link: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30082-2/fulltext
Download Text:
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
astra-migrate-meta-layouts: set
Scroll to Top